Featured Research

from universities, journals, and other organizations

Fetal Cell Therapy Benefits Some Parkinson's Patients

Date:
April 26, 1999
Source:
NIH-National Institute Of Neurological Disorders And Stroke
Summary:
Results from the first randomized, controlled clinical trial of fetal dopamine cell implants for Parkinson's disease show that the surgery helped a small number of Parkinson's patients, but not all who underwent the experimental therapy. These results raise important questions in the search for improved treatments for Parkinson's disease.

Results from the first randomized, controlled clinical trial of fetal dopamine cell implants for Parkinson's disease show that the surgery helped a small number of Parkinson's patients, but not all who underwent the experimental therapy. These results raise important questions in the search for improved treatments for Parkinson's disease.

Related Articles


The study, led by Curt Freed, M.D., at the University of Colorado in Denver, and Stanley Fahn, M.D., at Columbia-Presbyterian Medical Center in New York, included 40 patients with advanced Parkinson's disease. Half the patients received the cell implants, while half had a placebo surgery which appeared very similar to the implant procedure. The results will be announced today at the 51st annual meeting of the American Academy of Neurology in Toronto. The study was funded by the National Institute of Neurological Disorders and Stroke (NINDS).

The 40 patients in this study were randomly selected to receive either the cell therapy or the placebo. Patients in the implant group received injections of dopamine-producing cells into the putamen, the area of the brain in which progressive loss of dopamine production triggers the symptoms of Parkinson's disease. Patients given the placebo surgery received four small cosmetic holes in the skull that looked like those made for the implant therapy but which did not penetrate the brain or its tough protective membrane, called the dura. All patients were informed of the risks of the surgery and the possibility that they might initially be in the non-therapeutic placebo group. The patients were evaluated periodically for 1 year after the procedure before they learned whether or not they had received the cell implant therapy. Those originally in the placebo group were then given the opportunity to receive the cell transplants.

After 1 year, the treated patients under age 60 (9 of the total patients in the trial) showed significant improvements in movement. Patients over age 60 who received the implants, as well as those who had the placebo surgery, showed no significant improvements in any of their symptoms. On another important measure, the study showed that patients did not perceive a benefit from the therapy in terms of their normal daily activities.

"Any gains against this terrible, common disorder are welcome," said Gerald Fischbach, M.D., Director of NINDS. "We are proud to be the sponsors of this trial. Although not all measured outcomes were positive, there was clear improvement in control of movement in Parkinson's patients 60 years of age or younger. There is reason to be encouraged."

PET brain scans showed that more than half of the patients who received the implants had a greater than 20 percent increase in dopamine activity in the putamen, regardless of age. There were no significant surgical complications during this clinical trial, confirming that both the implant and the placebo surgery are safe when performed by an experienced surgeon. While there were significantly more severe adverse experiences during the 1-year follow-up period in patients who received the implants than in those who received placebo, these severe adverse experiences showed no consistent or logical pattern that could be associated with the surgery or the implant. "Further studies must clarify adverse reactions which are seemingly unrelated but cannot be ignored," said Dr. Fischbach.

Previous studies of fetal dopamine cells for Parkinson's disease in the 1980s and 1990s showed what sometimes appeared to be remarkable benefits. Dopamine is a nerve-signalling chemical, or neurotransmitter, that influences many parts of the brain, including those that control movement. Publicity surrounding these early clinical trial results led to great patient demand for cell implant therapy. Until now, however, researchers could not be certain whether the effects seen in these earlier clinical trials were due to the therapy or to psychological factors.

The 5-year, $5.7 million trial was the first clinical study of fetal tissue implants to receive federal research funding after a ban on funding of this type of research was lifted in 1993. The current Congressional prohibition on use of federal funds for human embryo research extends only to studies in which a human embryo is created for research purposes or is subjected to risks greater than those allowed for fetuses in utero.

In addition to Dr. Freed and his colleague Robert Breeze, M.D., at the University of Colorado, the research team included Dr. Fahn and colleagues at Columbia-Presbyterian Medical Center, who performed all clinical evaluations of the patients, and David Eidelberg, M.D., and colleagues at North Shore University Hospital -- Cornell University Medical College, Long Island, who performed the PET brain scans to detect any changes in dopamine activity. This collaboration helped ensure that neither the researchers who evaluated the patients nor the patients themselves knew who had received the treatment or the placebo.

While the study results indicate that fetal cell implants can help some patients younger than age 60, they also raise important questions, including why the treatment did not benefit older patients. Furthermore, the implants did not reduce the need for any drugs that patients in the study were taking for Parkinson's disease. The next steps will be to determine whether the benefits last over time, whether other therapies are more beneficial, and whether there might be different forms of Parkinson's disease depending on the age of the patient. More analysis of the results from this trial and additional years of patient follow-up are needed to answer these questions. A second NINDS-funded clinical trial of 36 patients, led by Charles W. Olanow, M.D., at Mt. Sinai Medical Center in New York, is under way and may yield additional information. However, the results of that study are not expected until 2001.


Story Source:

The above story is based on materials provided by NIH-National Institute Of Neurological Disorders And Stroke. Note: Materials may be edited for content and length.


Cite This Page:

NIH-National Institute Of Neurological Disorders And Stroke. "Fetal Cell Therapy Benefits Some Parkinson's Patients." ScienceDaily. ScienceDaily, 26 April 1999. <www.sciencedaily.com/releases/1999/04/990426063039.htm>.
NIH-National Institute Of Neurological Disorders And Stroke. (1999, April 26). Fetal Cell Therapy Benefits Some Parkinson's Patients. ScienceDaily. Retrieved November 26, 2014 from www.sciencedaily.com/releases/1999/04/990426063039.htm
NIH-National Institute Of Neurological Disorders And Stroke. "Fetal Cell Therapy Benefits Some Parkinson's Patients." ScienceDaily. www.sciencedaily.com/releases/1999/04/990426063039.htm (accessed November 26, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, November 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com
Madagascar Working to Contain Plague Outbreak

Madagascar Working to Contain Plague Outbreak

AFP (Nov. 24, 2014) Madagascar said Monday it is trying to contain an outbreak of plague -- similar to the Black Death that swept Medieval Europe -- that has killed 40 people and is spreading to the capital Antananarivo. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com
Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins